reason report
intern investig reflect still-strong underli
bottom line share sold today back
announc around intern investig histor report
foreign currenc gain remain confid compani underli
fundament surpris investig overshadow
otherwis solid quarter insert uncertainti stori
primarili around histor ep impact right way think
ep go forward exactli know answer
question said look nois around
oper margin came ahead consensu --
highlight believ build momentum
appear durabl head high level enter
new headwind aris tough comp acut
surgeri due competitor suppli issu feel headwind start
eas in-cent hemodialysi brevibloc recent/new product
launch ramp myxredlin prismax renal
new pump platform medic deliveri acknowledg
uncertainti around on-going investig like
keep share bit rangebound given believ
strong underli fundament -- regardless outcom
investig -- believ share ultim move
meaning higher current level investig
resolv fundament start matter
reiter op pt lower pt
-- previous -- rang dcf valuat
deriv base case upsid scenario supplement
ev/fcf ev/ebitda analys estim
ev/ebitda perspect pt appli multipl
ebitda estim repres modest multipl expans
current level ev/ebitda ebitda
multipl line large-cap med-tech group
growth acceler think multipl expans within
group averag justifi
sale estim updat reflect current guidanc
modestli lower y/i oper report
larg reflect result sale estim
move y/i report given
impact histor ep rel unpredict intern
investig still on-going suspend ep estim pend
clariti
medic suppli devic
deriv dcf valuat rang
supplement ev/fcf ev/
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target believ sale
growth acceler stori remain underappreci street bax lrp sale
compound-annual-growth-rate time-frame oper margin ramp
immedi post-spin us well-posit
exit lrp long-rang plan near top-lin growth organ ahead
overal med-tech market mid-single-digit rang possibl even faster growth overal via
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid current long-term growth margin target
believ margin expans stori alreadi least partli price stock
manag current guid oper margin
see room upsid margin ramp believ major upsid
alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
addit strong free cash flow gener capabl free cash flow target
vs potenti upsid free cash flow view
increas financi flexibl invest busi drive even faster sale
growth acceler invest inorgan outsid opportun supplement top-
bottom-lin growth
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade
rang dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys ev/ebitda perspect pt
appli multipl ebitda estim repres modest multipl
expans current level ev/ebitda ebitda
multipl line large-cap med-tech group ew
sale growth acceler think multipl
expans group averag justifi
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
note report non-oper item ep preliminari result
consensu detail revenu item visibl alpha
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
note report non-oper item ep preliminari result
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except asp
good sold
research develop expens
sg sale
 sale
oper expens sale
compani report svb leerink estim
constant currenc
revenu report
revenu report
constant currenc
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
revenu report
constant currenc basi flat
oper
report
constant currenc oper
margin expans
flat report
constant currenc basi
flat report
constant currenc basi
margin expans
margin expans
report constant
currenc basi oper
margin expans
bp
currenc basi
report constant
margin expans
bp
report impli
mid-point
constant currenc basi
margin expans
bp
report impli
mid-point
constant currenc basi
margin expans
bp
oper cf
ex
oper cf
ex
oper cf
ex
oper cf
cap ex
oper cf
cap ex
oper cf
ex
oper cf
ex
compani report svb leerink estim
basi
low-single-digit constant
cyclo msd increas
constant
currenc basi
basi
low-single-digit declin
includ cyclo
constant
currenc basi
vs lsd
basi
declin constant
cyclo vs
constant
currenc basi
digit constant
high-single-digit growth
oper
includ cyclo
digit constant
currenc basi
hsd constant currenc
basi
constant
basi
constant
basi
constant currenc
basi includ
recothrom
constant
basi
constant
oper
constant currenc
basi includ cyclo
constant
currenc basi
recothrom
preveleak
constant
currenc basi
constant currenc
basi
basi oper
basi
constant
currenc basi
basi
constant
constant
point-of-car solut pd
innov home periton dialysi pd solut system
improv patient access home dialysi new system
design produc steril pd solut use small water filtrat
devic would place patient home integr
sharesourc telehealth platform
final regulatori pathway fda on-
demand periton dialysi pd system drug-devic combo
expect start clinic trial
 januari announc enrol first
patient clinic trial
oct note market share leader
pd global even introduct poc pd
like grow market rate
hdx therapi enabl
hdx therapi extend rang molecul filter
blood dialysi result filtrat profil
close mimic natur kidney addit clearanc profil
hdx enabl theranova simpl perform
convent hemodialysi hd design work
hd machin allow clinic offer hdx therapi use exist
resourc elimin need special equip ad
clinic workflow requir hdf addit hdf
perform effect patient hdx therapi enabl
theranova crucial step bring benefit theranova
patient market
octob begun enrol patient us
januari expect launch
 octob push timelin
expect new product pipelin acceler growth
contribut busi
compani report svb leerink estim
first set use continu renal replac therapi
crrt sepsi manag protocol label expans
oxiri blood purif set add baxter multi-organ
therapi offer util prismaflex system
oxiri label expans take effect
countri europ well geographi
east africa began launch label expans
select market outsid
roll-out on-go
februari began limit launch
anticip full european launch later year
expect improv outcom convent
hemodialysi use particular dialyz get
better level clearanc certain molecul
latest technolog acut care therapi
new dialyz could chang game long-term term
hd expect provid uniqu advantag
amia integr sharesourc technolog allow
patient clinician commun back forth daili
may convert roughli patient
 expect acceler
also sharesourc technolog
compani report svb leerink estim
